SHEZF's Current Ratio is ranked better than 53.77% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs SHEZF: 2.15
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Shenzhen Hepalink Pharmaceutical Group Co Current Ratio Related Terms
Shenzhen Hepalink Pharmaceutical Group Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co Current Ratio Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co Current Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Current Ratio of 2.15 as of Mar. 2026. This is near median its historical median of 2.28. Over the past decade, Shenzhen Hepalink Pharmaceutical Group Co's Current Ratio has ranged from 1.01 to 3.37. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #460 out of 995 companies in the Drug Manufacturers industry, placing it in the top 46.2%.
Is Shenzhen Hepalink Pharmaceutical Group Co's Current Ratio too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Current Ratio of 2.15 is near median its 10-year median of 2.28. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 3.37. The Drug Manufacturers industry median Current Ratio is 2.00. Shenzhen Hepalink Pharmaceutical Group Co's value of 2.15 is 7.5% above this industry median. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #460 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #460 out of 995 companies for Current Ratio. This puts Shenzhen Hepalink Pharmaceutical Group Co in the upper half of its industry. The industry median Current Ratio is 2.00. Shenzhen Hepalink Pharmaceutical Group Co's value of 2.15 is 7.5% above this benchmark. Historically, Shenzhen Hepalink Pharmaceutical Group Co's own Current Ratio has ranged from 1.01 to 3.37 over the past decade. While the company's 10-year median is 2.28 vs. the industry median of 2.00, Shenzhen Hepalink Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current Current Ratio of 2.15 is 7.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current Current Ratio is 2.15, which is near median its own 10-year median of 2.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Current Ratio of 2.15. The stock's GF Value™ is $0.61, compared to a current price of $0.47 — trading 23% below its estimated fair value. The current Current Ratio is 2.15, which is near median its 10-year median of 2.28 and 7.5% above the Drug Manufacturers industry median of 2.00. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Current Ratio is 2.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 23% below its estimated GF Value™ of $0.61.
Key valuation signals for SHEZF:
Current Ratio: 2.15 (near median its 10-year median of 2.28)
GF Value™: $0.61 vs. price of $0.47 (23% below fair value)
Industry Position: 7.5% above the Drug Manufacturers median (#460 of 995)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
69GF Score
Get the complete analysis for SHEZF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
